Trials / Completed
CompletedNCT00645281
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
Symptom Specific Effectiveness of Tolterodine ER 4 mg in Patients With Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open-label, Single-arm, Non-randomized, Trial in Adult Patients With OAB.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 896 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolterodine extended release | Tolterodine ER capsule 4 mg daily for 12 weeks |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-01-01
- First posted
- 2008-03-27
- Last updated
- 2021-01-27
Locations
96 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00645281. Inclusion in this directory is not an endorsement.